NOVO-NORDISK AS revenue for the last year amounted to 31.15 B EUR, the most of which — 28.85 B EUR — came from its highest performing source at the moment, Diabetes and Obesity Care, the year earlier bringing 20.97 B EUR. The greatest contribution to the revenue figure was made by United States — last year it brought NOVO-NORDISK AS 17.10 B EUR, and the year before that — 11.35 B EUR.